person · Reporting owner
Moore Matthew Richard
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | SVP and Chief Business Officer | May 01, 2024 | May 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date May 01, 2024 · Filed May 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 145,505 |
Ending reported balance
After 2024-05-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-05-01 · Grant · Acquired 4,166 · Balance 150,186 F1: Represents Restricted Stock Units ("RSUs"), initial grant on February 22, 2024, that were subject to a performance-based vesting condition, that was determined to be satisfied on the Vesting Commencement Date, May 1, 2024. F2: The RSUs will vest in twelve equal quarterly installments on the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer on each vesting date. Row 2 · 2024-05-02 · Sale · Disposed 4,681 · Balance 145,505 F3: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the RSUs, the shares were sold upon the vesting of the RSUs solely to cover applicable tax withholding. F4: The transaction was executed in multiple trades in prices ranging from $8.47 to $9.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units ("RSUs"), initial grant on February 22, 2024, that were subject to a performance-based vesting condition, that was determined to be satisfied on the Vesting Commencement Date, May 1, 2024.
F2: The RSUs will vest in twelve equal quarterly installments on the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the RSUs, the shares were sold upon the vesting of the RSUs solely to cover applicable tax withholding.
F4: The transaction was executed in multiple trades in prices ranging from $8.47 to $9.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ventyx Biosciences, Inc.
Report date March 04, 2026 · Filed March 04, 2026
Section 16 reporting ended · disclosed 2026-03-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2035-01-02 | Direct | 0 |
Reported balance
After 2026-03-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-04 · Disposition to issuer · Disposed 145,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.98 · Expires 2034-05-16 | Direct | 0 |
Reported balance
After 2026-03-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-04 · Disposition to issuer · Disposed 320,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent.
F2: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 4, 2026 21:30 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | Disposition to issuerStock Option (Right to Buy) · Derivative | 320,000 | Not disclosed Strike: $4.98 | Not disclosed |
DisclosureSEC source: 0001840191-26-000002 · form4-03042026_090329.xml · derivative · entry 2 Moore Matthew Richard · CIK 0001840191 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 320,000 shares Expires 2034-05-16 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2 · price: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes. F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes. Read SEC document |
| March 04, 2026 Filed Mar 4, 2026 21:30 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | Disposition to issuerStock Option (Right to Buy) · Derivative | 145,000 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001840191-26-000002 · form4-03042026_090329.xml · derivative · entry 1 Moore Matthew Richard · CIK 0001840191 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 145,000 shares Expires 2035-01-02 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent. F2 · price: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes. F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:53 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | GrantStock Option (Right to Buy) · Derivative | 145,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-25-000648 · form4-01032025_110122.xml · derivative · entry 1 Moore Matthew Richard · CIK 0001840191 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2035-01-02 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the total shares subject to the Option shall vest each month following the Vesting Commencement Date (as defined below) on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date. The Vesting Commencement Date is January 2, 2025. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:20 UTC | Ventyx Biosciences, Inc. VTYX · Entity 62843 | GrantStock Option (Right to Buy) · Derivative | 320,000 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001415889-24-013502 · form4-05172024_080532.xml · derivative · entry 1 Moore Matthew Richard · CIK 0001840191 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 320,000 shares Expires 2034-05-16 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 16, 2024. Read SEC document |
| May 02, 2024 Filed May 3, 2024 20:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 4,681 | $8.74 | $40,901.64 |
DisclosureSEC source: 0001787306-24-000072 · wk-form4_1714768141.xml · nonDerivative · entry 2 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,505 F3 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the RSUs, the shares were sold upon the vesting of the RSUs solely to cover applicable tax withholding. F4 · price: The transaction was executed in multiple trades in prices ranging from $8.47 to $9.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000072 · wk-form4_1714768141.xml · nonDerivative · entry 1 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,186 F1 · kind: Represents Restricted Stock Units ("RSUs"), initial grant on February 22, 2024, that were subject to a performance-based vesting condition, that was determined to be satisfied on the Vesting Commencement Date, May 1, 2024. F2 · shares: The RSUs will vest in twelve equal quarterly installments on the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 22:08 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,468 | $11.12 | $38,568.32 |
DisclosureSEC source: 0001787306-24-000036 · wk-form4_1709762890.xml · nonDerivative · entry 1 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,020 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units. F2 · price: The transaction was executed in multiple trades in prices ranging from $11.000 to $11.3200, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,500 | Not disclosed Strike: $28.72 | Not disclosed |
DisclosureSEC source: 0001787306-24-000022 · wk-form4_1708040852.xml · derivative · entry 10 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2031-01-18 F4 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, performance-based option granted to the Reporting Person on January 19, 2021, and deemed earned on August 29, 2023, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024. F9 · derivative.exercise_date: The canceled option vested as to 1/48 of the shares vest on each monthly anniversary of the milestone vesting commencement date, beginning on September 29, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (Right to Buy) · Derivative | 39,500 | Not disclosed Strike: $15.82 | Not disclosed |
DisclosureSEC source: 0001787306-24-000022 · wk-form4_1708040852.xml · derivative · entry 9 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,500 shares Expires 2033-03-02 F3 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023, and received in exchange for the option, these RSUs that vest in twelve equal quarterly installments commencing May 1, 2024. F8 · derivative.exercise_date: The canceled option vested as to 1/48 of the shares vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (Right to Buy) · Derivative | 35,300 | Not disclosed Strike: $17.67 | Not disclosed |
DisclosureSEC source: 0001787306-24-000022 · wk-form4_1708040852.xml · derivative · entry 8 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,300 shares Expires 2032-03-03 F2 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024. F7 · derivative.exercise_date: The canceled option vested as to 1/48 of the shares vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (Right to Buy) · Derivative | 80,000 | Not disclosed Strike: $28.72 | Not disclosed |
DisclosureSEC source: 0001787306-24-000022 · wk-form4_1708040852.xml · derivative · entry 7 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2031-01-19 F1 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on January 19, 2021, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in eight equal quarterly installments commencing May 1, 2024. F6 · derivative.exercise_date: The canceled option vested as to 1/4 of the total shares on January 11, 2022, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vesting on January 11, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Disposition to issuerStock Option (Right to Buy) · Derivative | 80,000 | Not disclosed Strike: $28.72 | Not disclosed |
DisclosureSEC source: 0001787306-24-000022 · wk-form4_1708040852.xml · derivative · entry 6 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2031-01-19 F1 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on January 19, 2021, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in eight equal quarterly installments commencing May 1, 2024. F5 · derivative.exercise_date: The canceled option vested as to 1/4 of the total shares on July 20, 2021, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vesting on July 20, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787306-24-000022 · wk-form4_1708040852.xml · nonDerivative · entry 5 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,488 F4 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, performance-based option granted to the Reporting Person on January 19, 2021, and deemed earned on August 29, 2023, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 19,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787306-24-000022 · wk-form4_1708040852.xml · nonDerivative · entry 4 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,322 F3 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 2, 2023, and received in exchange for the option, these RSUs that vest in twelve equal quarterly installments commencing May 1, 2024. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 17,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787306-24-000022 · wk-form4_1708040852.xml · nonDerivative · entry 3 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,572 F2 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2022, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 26,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787306-24-000022 · wk-form4_1708040852.xml · nonDerivative · entry 2 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,922 F1 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on January 19, 2021, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in eight equal quarterly installments commencing May 1, 2024. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 26,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787306-24-000022 · wk-form4_1708040852.xml · nonDerivative · entry 1 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,256 F1 · price: On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on January 19, 2021, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in eight equal quarterly installments commencing May 1, 2024. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:28 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 126,000 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001787306-24-000004 · wk-form4_1705526921.xml · derivative · entry 2 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 0034-01-12 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 21:28 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000004 · wk-form4_1705526921.xml · nonDerivative · entry 1 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,590 F1 · shares: Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year, beginning on February 1, 2025, subject to the Reporting Person's continued service to the issuer. Read SEC document |
| August 29, 2023 Filed Sep 12, 2023 11:39 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $28.72 | $0.00 |
DisclosureSEC source: 0001787306-23-000092 · wk-form4_1694518782.xml · derivative · entry 1 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-01-18 F1 · shares: 1/48th of the shares vest on each monthly anniversary of the milestone vesting commencement date, beginning on September 29, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F1 · derivative.exercise_date: 1/48th of the shares vest on each monthly anniversary of the milestone vesting commencement date, beginning on September 29, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:54 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 39,500 | $0.00 Strike: $15.82 | $0.00 |
DisclosureSEC source: 0001567619-23-004543 · doc1.xml · derivative · entry 4 Moore Matthew Richard · CIK 0001840191 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,500 Underlying: Common Stock · 39,500 shares Expires 2033-03-02 F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:54 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 14,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-004543 · doc1.xml · nonDerivative · entry 3 Moore Matthew Richard · CIK 0001840191 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,590 F3 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 2 of each year, beginning March 2, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:54 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 21 | $16.52 | $346.92 |
DisclosureSEC source: 0001567619-23-004543 · doc1.xml · nonDerivative · entry 2 Moore Matthew Richard · CIK 0001840191 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,690 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:54 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 1,589 | $15.82 | $25,134.33 |
DisclosureSEC source: 0001567619-23-004543 · doc1.xml · nonDerivative · entry 1 Moore Matthew Richard · CIK 0001840191 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,711 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 01:46 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 35,300 | $0.00 Strike: $17.67 | $0.00 |
DisclosureSEC source: 0001567619-22-006491 · doc1.xml · derivative · entry 2 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,300 Underlying: Common Stock · 35,300 shares Expires 2032-03-03 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 01:46 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 13,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006491 · doc1.xml · nonDerivative · entry 1 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,300 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2023, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 13,300 RSUs. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 01:07 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $28.72 | $0.00 |
DisclosureSEC source: 0001567619-21-001353 · doc1.xml · derivative · entry 2 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-01-19 F2 · derivative.exercise_date: The option vests as to 1/4th of the total shares on January 11, 2022, and then 1/48th of the total shares monthly thereafter, with 100% of the total shares vested on January 11, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 01:07 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $28.72 | $0.00 |
DisclosureSEC source: 0001567619-21-001353 · doc1.xml · derivative · entry 1 Moore Matthew Richard · CIK 0001840191 · SVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-01-19 F1 · derivative.exercise_date: The option vests as to 1/4th of the total shares on July 20, 2021, and then 1/48th of the total shares monthly thereafter, with 100% of the total shares vested on July 20, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.